Vir Biotechnology Inc (VIR)

Jan 13, 2025, 6:10 PM EST - 4 days ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 10, 2025, 2:32 PM EST - 7 days ago

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

Jan 9, 2025, 9:00 AM EST - 8 days ago

Vir Biotechnology: A Rocket Off Phase 1 Data

Jan 8, 2025, 12:28 PM EST - 9 days ago

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

Jan 8, 2025, 7:45 AM EST - 9 days ago

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Dec 18, 2024, 9:30 AM EST - 4 weeks ago

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 12:57 PM EST - 5 weeks ago

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Dec 12, 2024, 4:05 PM EST - 5 weeks ago

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Nov 26, 2024, 9:30 AM EST - 7 weeks ago

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Nov 25, 2024, 9:30 AM EST - 7 weeks ago

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 9:15 PM EST - 2 months ago

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Nov 18, 2024, 4:05 PM EST - 2 months ago

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Nov 15, 2024, 11:00 AM EST - 2 months ago

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Nov 5, 2024, 11:29 AM EST - 2 months ago

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Oct 31, 2024, 11:12 PM EDT - 2 months ago

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 4:05 PM EDT - 2 months ago

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 17, 2024, 4:30 PM EDT - 3 months ago

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Oct 15, 2024, 8:16 AM EDT - 3 months ago

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024

Oct 3, 2024, 4:00 PM EDT - 3 months ago

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Sep 10, 2024, 8:05 AM EDT - 4 months ago

Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

Sep 9, 2024, 4:05 PM EDT - 4 months ago

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Aug 22, 2024, 8:05 AM EDT - 5 months ago

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 1, 2024, 10:10 PM EDT - 6 months ago

Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:02 PM EDT - 6 months ago

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

Aug 1, 2024, 4:01 PM EDT - 6 months ago

Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers

Jul 18, 2024, 4:05 PM EDT - 6 months ago

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

Jul 17, 2024, 4:47 PM EDT - 6 months ago

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

Jun 26, 2024, 8:05 AM EDT - 7 months ago

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Jun 5, 2024, 5:30 AM EDT - 8 months ago

Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment

May 29, 2024, 4:05 PM EDT - 8 months ago

Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 29, 2024, 8:05 AM EDT - 8 months ago

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer

May 23, 2024, 4:05 PM EDT - 8 months ago

Vir Biotechnology to Host 2024 Annual Meeting of Stockholders

May 22, 2024, 8:05 AM EDT - 8 months ago

Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

May 22, 2024, 8:00 AM EDT - 8 months ago

Reser's Fine Foods Kicks Off 2024 ‘Good Times Tour'

SAIC

May 21, 2024, 8:17 AM EDT - 8 months ago

Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024

May 13, 2024, 7:21 PM EDT - 8 months ago

Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies

May 3, 2024, 12:35 AM EDT - 9 months ago

Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 9 months ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results

Apr 30, 2024, 4:05 PM EDT - 9 months ago

Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024

Apr 18, 2024, 8:00 AM EDT - 9 months ago

Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D.

Apr 11, 2024, 4:30 PM EDT - 10 months ago

Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024

Mar 5, 2024, 8:05 AM EST - 11 months ago

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

Feb 27, 2024, 11:56 PM EST - 11 months ago

Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta

Feb 23, 2024, 8:05 AM EST - 11 months ago

Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences

Feb 22, 2024, 8:48 PM EST - 11 months ago

Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:05 PM EST - 11 months ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 1, 2024, 4:05 PM EST - 1 year ago

Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024

Dec 26, 2023, 12:18 PM EST - 1 year ago

20 favorite small-cap stocks for 2024 among Wall Street analysts

ARLO CPRX DGII DVAX GPRE HLX IRWD

Dec 13, 2023, 4:05 PM EST - 1 year ago

Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation

Dec 6, 2023, 4:05 PM EST - 1 year ago

Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference